For Novartis, No Relax’in On Serelaxin: More Trials Likely
This article was originally published in The Pink Sheet Daily
Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.
You may also be interested in...
While on paper a surrogate endpoint was OK with the agency, company’s attempt to advance endpoint by incorporating clinical outcomes gets pushback from FDA and its advisors.
Advisory committee rejects heart failure treatment but expects drug may show success if evaluated on harder clinical endpoints.
FDA recommends against approval of Novartis’ heart failure drug serelaxin in run up to advisory panel, signaling company may need second Phase III study just beginning to get drug okayed.